Amgen: Phase 3 Study of Kyprolis, Darzalex Meets Primary Endpoint
13 September 2019 - 11:51PM
Dow Jones News
By Colin Kellaher
Amgen Inc. (AMGN) on Friday said a phase 3 study evaluating its
cancer drug Kyprolis in combination with dexamethasone and Johnson
& Johnson's (JNJ) Darzalex compared with Kyprolis and
dexamethasone alone met its primary endpoint of progression-free
survival.
The Thousand Oaks, Calif., biotechnology company said the
regimen resulted in a 37% reduction in the risk of progression or
death in patients with relapsed or refractory multiple myeloma, a
cancer that forms in a type of white blood cells called plasma
cells and causes cancer cells to accumulate in the bone marrow.
Amgen said the phase 3 study confirms the benefit for patients
shown in an earlier phase 1 study using the same combination,
adding that it plans to discuss the data with health authorities in
preparation for regulatory submissions.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 13, 2019 09:36 ET (13:36 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to May 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2023 to May 2024